ArticleFrontiers in pharmacology2025
Topical frankincense treatment on relieving high-risk diabetic foot in rats by reducing inflammation and improving microcirculation.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Metabolism, senescence, and natural products: new perspectives on wound healing in diabetes.Frontiers in nutrition · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Frankincense, an ancient aromatic substance known for promoting blood circulation, is widely used in traditional Chinese medicine to treat skin lesions. Methods: This study aimed to evaluate the efficacy and underlying mechanisms of frankincense oil extract (FOE) in addressing high-risk diabetic foot by improving microvascular circulatory disorders. The vascular repair effects of FOE were assessed in a streptozotocin-induced high-risk diabetic foot animal model. Various evaluations were performed, including infrared thermometry, motor nerve conduction velocity (MNCV) testing, laser Doppler flowmetry (LDF), hematoxylin and eosin (H&E) staining, and immunohistochemical analyses for CD31, TRPV3, β-catenin, MMP-9, and COX-2 expressions. Results: The results showed that, the femoral arteries, plantar arteries, and microvessels in high-risk diabetic foot rats displayed significant damage, evidenced by reduced blood flow velocity, ruptured vascular intima, and disorganized endothelial fibers. FOE treatment restored temperature and blood flow velocity in the foot and increased MNCV. Furthermore, FOE improved blood circulation, reversed the reduced expression of CD31, enhanced nerve sensitivity by up-regulating TRPV3 expression, and exhibited anti-inflammatory effects by reducing the overexpression of β-catenin, MMP-9, and COX-2. Conclusion: FOE effectively prevents high-risk diabetic foot by repairing vascular damage, restoring blood circulation, enhancing nerve sensitivity, and suppressing inflammatory cell infiltration. Therefore, these findings highlight the potential clinical value of FOE in managing diabetic complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.